title: Effect of iridoid glucoside on plasma lipid profile, tissue fatty acid changes, inflammatory cytokines, and GLUT4 expression in skeletal muscle of streptozotocin-induced diabetic rats.
abstract: The present study was designed to examine the antihyperlipidaemic potential of iridoid glucoside isolated from Vitex negundo leaves in STZ-induced diabetic rats. The levels of cholesterol (TC), triglycerides, lipoproteins, free fatty acids, phospholipids, fatty acid composition, proinflammatory cytokines, muscle glycogen content, and glucose transporter 4 (GLUT4) expression were estimated in control and diabetic rats. Oral administration of iridoid glucoside at a dose of 50 mg/kg body weight per day to STZ-induced diabetic rats for a period of 30 days resulted in a significant reduction in plasma and tissue (liver and kidney) cholesterol, triglycerides, free fatty acids, and phospholipids. In addition, the decreased plasma levels of high-density lipoprotein-cholesterol and increased plasma levels of low density lipoprotein- and very low density lipoprotein-cholesterol in diabetic rats were restored to near normal levels following treatment with iridoid glucoside. The fatty acid composition of the liver and kidney was analyzed by gas chromatography. The altered fatty acid composition in the liver and kidney of diabetic rats was also restored upon treatment with iridoid glucoside. Moreover, the elevated plasma levels of proinflammatory cytokines and decreased levels of muscle glycogen and GLUT4 expression in the skeletal muscle of diabetic rats were reinstated to their normal levels via enhanced secretion of insulin from the remnant β cells of pancreas by the administration of iridoid glucoside. The effect produced by iridoid glucoside on various parameters was comparable with that of glibenclamide, a well-known antihyperglycemic drug.
authors.affiliation: Department of Medical Biochemistry, Dr. ALM P-G, Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai 600113, Tamil Nadu, India.
authors.forename: Ramalingam
authors.initials: R
authors.lastname: Sundaram
authors.forename: Palanivelu
authors.initials: P
authors.lastname: Shanthi
authors.forename: Panchanatham
authors.initials: P
authors.lastname: Sachdanandam
mesh_terms: D000818:Animals; D015153:Blotting, Western; D002784:Cholesterol / Q000097:blood / Q000378:metabolism; D016207:Cytokines / Q000097:blood*; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000378:metabolism / Q000517:prevention & control*; D004797:Enzyme-Linked Immunosorbent Assay; D005227:Fatty Acids / Q000097:blood / Q000378:metabolism*; D051275:Glucose Transporter Type 4 / Q000096:biosynthesis*; D005905:Glyburide / Q000008:administration & dosage / Q000494:pharmacology; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology; D018836:Inflammation Mediators / Q000097:blood; D057888:Iridoid Glucosides / Q000008:administration & dosage / Q000494:pharmacology*; D007668:Kidney / Q000187:drug effects; D008055:Lipids / Q000097:blood*; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008297:Male; D018482:Muscle, Skeletal / Q000187:drug effects* / Q000378:metabolism; D010179:Pancreas / Q000187:drug effects / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D014280:Triglycerides / Q000097:blood / Q000378:metabolism
chemical_list: D016207:Cytokines; D005227:Fatty Acids; D051275:Glucose Transporter Type 4; D007004:Hypoglycemic Agents; D018836:Inflammation Mediators; D057888:Iridoid Glucosides; D008055:Lipids; C495694:Slc2a4 protein, rat; D014280:Triglycerides; D002784:Cholesterol; D005905:Glyburide